These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
45. Expanding the spectrum of neuromyelitis optica: friend or foe? Behbehani R Curr Opin Ophthalmol; 2007 Nov; 18(6):459-62. PubMed ID: 18162996 [TBL] [Abstract][Full Text] [Related]
46. Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype. Kitley J; Woodhall M; Waters P; Leite MI; Devenney E; Craig J; Palace J; Vincent A Neurology; 2012 Sep; 79(12):1273-7. PubMed ID: 22914827 [TBL] [Abstract][Full Text] [Related]
47. Anti-MOG antibodies are present in a subgroup of patients with a neuromyelitis optica phenotype. Pröbstel AK; Rudolf G; Dornmair K; Collongues N; Chanson JB; Sanderson NS; Lindberg RL; Kappos L; de Seze J; Derfuss T J Neuroinflammation; 2015 Mar; 12():46. PubMed ID: 25889963 [TBL] [Abstract][Full Text] [Related]
48. Prediction of neuromyelitis optica attack severity by quantitation of complement-mediated injury to aquaporin-4-expressing cells. Hinson SR; McKeon A; Fryer JP; Apiwattanakul M; Lennon VA; Pittock SJ Arch Neurol; 2009 Sep; 66(9):1164-7. PubMed ID: 19752309 [TBL] [Abstract][Full Text] [Related]
49. Epidemiology of neuromyelitis optica in the United States: a multicenter analysis. Mealy MA; Wingerchuk DM; Greenberg BM; Levy M Arch Neurol; 2012 Sep; 69(9):1176-80. PubMed ID: 22733096 [TBL] [Abstract][Full Text] [Related]
50. Clinical Features of Patients with Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders. Chen H; Liu SM; Zhang XX; Liu YO; Li SZ; Liu Z; Dong HQ Chin Med J (Engl); 2016 Sep; 129(17):2079-84. PubMed ID: 27569235 [TBL] [Abstract][Full Text] [Related]
51. Comparison of myelin oligodendrocyte glycoprotein (MOG)-antibody disease and AQP4-IgG-positive neuromyelitis optica spectrum disorder (NMOSD) when they co-exist with anti-NMDA (N-methyl-D-aspartate) receptor encephalitis. Fan S; Xu Y; Ren H; Guan H; Feng F; Gao X; Ding D; Fang F; Shan G; Guan T; Zhang Y; Dai Y; Yao M; Peng B; Zhu Y; Cui L Mult Scler Relat Disord; 2018 Feb; 20():144-152. PubMed ID: 29414288 [TBL] [Abstract][Full Text] [Related]
52. Gender effect on neuromyelitis optica spectrum disorder with aquaporin4-immunoglobulin G. Kim SM; Waters P; Woodhall M; Kim YJ; Kim JA; Cheon SY; Lee S; Jo SR; Kim DG; Jung KC; Lee KW; Sung JJ; Park KS Mult Scler; 2017 Jul; 23(8):1104-1111. PubMed ID: 27760862 [TBL] [Abstract][Full Text] [Related]
53. Differential Effects of MS Therapeutics on B Cells-Implications for Their Use and Failure in AQP4-Positive NMOSD Patients. Traub J; Häusser-Kinzel S; Weber MS Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32708663 [TBL] [Abstract][Full Text] [Related]
54. Cognition in patients with neuromyelitis optica spectrum disorders: A prospective multicentre study of 217 patients (CogniNMO-Study). Hümmert MW; Stern C; Paul F; Duchow A; Bellmann-Strobl J; Ayzenberg I; Schwake C; Kleiter I; Hellwig K; Jarius S; Wildemann B; Senel M; Berthele A; Giglhuber K; Luessi F; Grothe M; Klotz L; Schülke R; Gingele S; Faiss JH; Walter A; Warnke C; Then Bergh F; Aktas O; Ringelstein M; Stellmann JP; Häußler V; Havla J; Pellkofer H; Kümpfel T; Kopp B; Trebst C Mult Scler; 2023 Jun; 29(7):819-831. PubMed ID: 36786424 [TBL] [Abstract][Full Text] [Related]